Mostrar el registro sencillo del ítem

dc.contributor.authorRadhoe, S.P.*
dc.contributor.authorVeenis, J.F.*
dc.contributor.authorJakus, N.*
dc.contributor.authorTimmermans, P.*
dc.contributor.authorPouleur, A.-C.*
dc.contributor.authorRubís, P.*
dc.contributor.authorVan Craenenbroeck, E.M.*
dc.contributor.authorGaizauskas, E.*
dc.contributor.authorBarge Caballero, Eduardo *
dc.contributor.authorPaolillo, S.*
dc.contributor.authorGrundmann, S.*
dc.contributor.authorD'Amario, D.*
dc.contributor.authorBraun, O.Ö.*
dc.contributor.authorGkouziouta, A.*
dc.contributor.authorPlaninc, I.*
dc.contributor.authorSamardzic, J.*
dc.contributor.authorMeyns, B.*
dc.contributor.authorDroogne, W.*
dc.contributor.authorWierzbicki, K.*
dc.contributor.authorHolcman, K.*
dc.contributor.authorFlammer, A.J.*
dc.contributor.authorGasparovic, H.*
dc.contributor.authorBiocina, B.*
dc.contributor.authorLund, L.H.*
dc.contributor.authorMilicic, D.*
dc.contributor.authorRuschitzka, F.*
dc.contributor.authorCikes, M.*
dc.contributor.authorBrugts, J.J.*
dc.date.accessioned2025-09-09T12:33:10Z
dc.date.available2025-09-09T12:33:10Z
dc.date.issued2023
dc.identifier.citationRadhoe SP, Veenis JF, Jakus N, Timmermans P, Pouleur A-C, Rubís P, et al. How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry. ESC Heart Failure. 2023;10(2):884-94.
dc.identifier.issn2055-5822
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/63a75a519ac45918ff1f80e2
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21570
dc.description.abstractAims: Use of left ventricular assist devices (LVADs) in older patients has increased, and assessing outcomes in older LVAD recipients is important. Therefore, this study aimed to investigate associations between age and outcomes after continuous-flow LVAD (cf-LVAD) implantation. Methods and results: Cf-LVAD patients from the multicentre European PCHF-VAD registry were included and categorized into those <50, 50-64, and ?65 years old. The primary endpoint was all-cause mortality. Among secondary outcomes were heart failure (HF) hospitalizations, right ventricular (RV) failure, haemocompatibility score, bleeding events, non-fatal thromboembolic events, and device-related infections. Of 562 patients, 184 (32.7%) were <50, 305 (54.3%) were aged 50-64, whereas 73 (13.0%) were ?65 years old. Median follow-up was 1.1 years. Patients in the oldest age group were significantly more often designated as destination therapy (DT) candidates (61%). A 10 year increase in age was associated with a significantly higher risk of mortality (hazard ratio [HR] 1.34, 95% confidence interval [CI] [1.15-1.57]), intracranial bleeding (HR 1.49, 95% CI [1.10-2.02]), and non-intracranial bleeding (HR 1.30, 95% CI [1.09-1.56]), which was confirmed by a higher mean haemocompatibility score (1.37 vs. 0.77, oldest vs. youngest groups, respectively, P = 0.033). Older patients suffered from less device-related infections requiring systemic antibiotics. No age-related differences were observed in HF-related hospitalizations, ventricular arrhythmias, pump thrombosis, non-fatal thromboembolic events, or RV failure. Conclusions: In the PCHF-VAD registry, higher age was associated with increased risk of mortality, and especially with increased risk of major bleeding, which is particularly relevant for the DT population. The risks of HF hospitalizations, pump thrombosis, ventricular arrhythmia, or RV failure were comparable. Strikingly, older patients had less device-related infections.
dc.languageeng
dc.rightsAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.meshHumans *
dc.subject.meshAged *
dc.subject.meshHeart-Assist Devices *
dc.subject.meshTreatment Outcome *
dc.subject.meshHeart Failure *
dc.subject.meshArrhythmias, Cardiac*
dc.subject.meshRegistries *
dc.subject.meshThrombosis *
dc.titleHow does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry
dc.typeArtigo
dc.authorsophosRadhoe, S.P.; Veenis, J.F.; Jakus, N.; Timmermans, P.; Pouleur, A.-C.; Rubís, P.; Van Craenenbroeck, E.M.; Gaizauskas, E.; Barge-Caballero, E.; Paolillo, S.; Grundmann, S.; D'Amario, D.; Braun, O.Ö.; Gkouziouta, A.; Planinc, I.; Samardzic, J.; Meyns, B.; Droogne, W.; Wierzbicki, K.; Holcman, K.; Flammer, A.J.; Gasparovic, H.; Biocina, B.; Lund, L.H.; Milicic, D.; Ruschitzka, F.; Cikes, M.; Brugts, J.J.
dc.identifier.doi10.1002/ehf2.14247
dc.identifier.sophos63a75a519ac45918ff1f80e2
dc.issue.number2
dc.journal.titleESC Heart Failure*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario A Coruña::Cardioloxía
dc.page.initial884
dc.page.final894
dc.relation.publisherversionhttps://doi.org/10.1002/ehf2.14247
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS A Coruña
dc.subject.keywordCHUAC
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number10


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)